A venture capital firm based in Cambridge, MA raised a new fund in 2015, which closed at $500 million. The firm makes highly varied allocations, and focuses on investing in North American biotech hubs (including Boston, the San Francisco Bay Area, and San Diego), but also considers opportunities elsewhere in North America and in Europe.
The firm invests in therapeutic companies with products at the preclinical development stage. The firm typically invests in biologics and NCEs rather than optimizations of existing chemical entities. The firm is opportunistic regarding indication areas but focuses on oncology, CNS, anti-infectives, and other serious life-threatening diseases (including orphan diseases), and generally does not invest in fields that require large Phase III trials such as cardiology and diabetes.
The firm seeks companies pursuing disease targets that have been rigorously validated via animal studies, pharmacology and/or genetic studies. The firm invests in high-quality management teams, and syndicates investments with a select group of preferred strategic and financial investors.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com
Next Phase Newsletter 
Leave a comment